Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Phapros TbkISX:PEHA +1.32%76 EV-to-EBITDA is 7.19 as of Sep. 02, 2026, which is 36% below its 10-year median of 11.29. GuruFocus rates ISX:PEHA with a GF Score™ of 76/100 and a GF Value™ of Rp380.61 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 729 Drug Manufacturers companies, PT Phapros Tbk ranks better than 74.9% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PT Phapros Tbk's enterprise value is Rp856,585 Mil.
PT Phapros Tbk's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was Rp119,081 Mil. Therefore, PT Phapros Tbk's EV-to-EBITDA for today is 7.19.
The historical rank and industry rank for PT Phapros Tbk's EV-to-EBITDA or its related term are showing as below:
ISX:PEHA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -4.84 Med: 11.29 Max: 63.92
Current: 7.2
During the past 13 years, the highest EV-to-EBITDA of PT Phapros Tbk was 63.92. The lowest was -4.84. And the median was 11.29.
ISX:PEHA's EV-to-EBITDA is ranked better than 74.9% of 729
companies
in the Drug Manufacturers industry
Industry Median: 13.48
vs ISX:PEHA: 7.20
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PT Phapros Tbk's PE Ratio (TTM) for today is calculated as:
PT Phapros Tbk's share price for today is Rp308.00.
PT Phapros Tbk's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp41.681.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for PT Phapros Tbk's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:PEHA vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PT Phapros Tbk's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Phapros Tbk EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Phapros Tbk's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PT Phapros Tbk's EV-to-EBITDA falls into.
PT Phapros Tbk's current Enterprise Value is Rp856,585 Mil.
PT Phapros Tbk's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp119,081 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Phapros Tbk (ISX:PEHA) has a EV-to-EBITDA of 7.19 as of Sep. 02, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PT Phapros Tbk. This is 36% below median its historical median of 11.29. According to the industry distribution chart, PT Phapros Tbk ranks #183 out of 729 companies in the Drug Manufacturers industry, placing it in the top 25.1%.
Is PT Phapros Tbk's EV-to-EBITDA too high?
PT Phapros Tbk's current EV-to-EBITDA of 7.19 is 36% below median its 10-year median of 11.29. The Drug Manufacturers industry median EV-to-EBITDA is 13.48. PT Phapros Tbk's value of 7.19 is 46.7% below this industry median. Based on the distribution chart, PT Phapros Tbk ranks #183 out of 729 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, PT Phapros Tbk has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Phapros Tbk's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PT Phapros Tbk ranks #183 out of 729 companies for EV-to-EBITDA. This puts PT Phapros Tbk in the upper half of its industry. The industry median EV-to-EBITDA is 13.48. PT Phapros Tbk's value of 7.19 is 46.7% below this benchmark. While the company's 10-year median is 11.29 vs. the industry median of 13.48, PT Phapros Tbk has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.48, based on 729 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Phapros Tbk's current EV-to-EBITDA of 7.19 is 46.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PT Phapros Tbk. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Phapros Tbk's current EV-to-EBITDA is 7.19, which is 36% below median its own 10-year median of 11.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Phapros Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Phapros Tbk (ISX:PEHA) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp380.61, compared to a current price of Rp308.00 — trading 19.1% below its estimated fair value. The current EV-to-EBITDA is 7.19, which is 36% below median its 10-year median of 11.29 and 46.7% below the Drug Manufacturers industry median of 13.48. PT Phapros Tbk's overall GF Score™ is 76/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For PT Phapros Tbk (ISX:PEHA), the current EV-to-EBITDA is 7.19 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Phapros Tbk (ISX:PEHA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Phapros Tbk stock appears to be undervalued.
The current stock price of Rp308.00 is trading 19.1% below its estimated GF Value™ of Rp380.61.
GuruFocus considers PT Phapros Tbk to be Modestly Undervalued.
Key valuation signals for ISX:PEHA:
EV-to-EBITDA: 7.19 (36% below median its 10-year median of 11.29)
GF Value™: Rp380.61 vs. price of Rp308.00 (19.1% below fair value)
Industry Position: 46.7% below the Drug Manufacturers median (#183 of 729)
No single metric tells the full story. See the ISX:PEHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Phapros Tbk is a pharmaceutical company in Indonesia. The company is engaged in the industrial/manufacturing sector by producing and/or trading medicines, health instruments, chemical goods, and other similar goods in import, export, and other kinds of industry. The company operates through Over Counter (OTC), Ethical, Generic Drugs Bearing (OGB), and Toll Manufacturing segments. It derives maximum revenue from OGB segment.
76GF Score
Get the complete analysis for ISX:PEHA
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:PEHA has been successfully added to your 
